Open access
Open access
Powered by Google Translator Translator

More data suggests no cardiovascular benefit from Omega-3 supplementation – secondary analysis of STRENGHT trial did not show an association between achieved Omega-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk.

8 Jun, 2021 | 09:19h | UTC

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial – JAMA Cardiology

Original study: #AHA20 – Randomized trial: High-dose Omega-3 fatty acids did not reduce the risk of cardiac events in patients at high cardiovascular risk

Commentaries: Higher blood levels of omega-3 fatty acids from prescription fish oil showed no effect on CV events – American College of Cardiology

 


Stay Updated in Your Specialty

No spam, just news.